Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH
暂无分享,去创建一个
S. Larson | J. Fagin | R. Tuttle | R. Robbins | H. Tala
[1] M. Schlumberger,et al. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] S. Larson,et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. , 2010, Thyroid : official journal of the American Thyroid Association.
[3] A. Driedger,et al. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. , 2006, Thyroid : official journal of the American Thyroid Association.
[4] M. Luster,et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.
[5] S. Larson,et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] Markus Luster,et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[8] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[9] M. Schlumberger,et al. The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma , 2005 .
[10] T. Heusner,et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[11] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[12] S. Larson,et al. Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.
[13] G. Karanikas,et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients , 2006, Clinical endocrinology.
[14] T. Pilli,et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.